Debate › Precautionary principle · Last reviewed 2026-05-17

The endocrinological double standard

Analysis of the inconsistency between the precautionary regime that has governed mainstream endocrinology since the Women's Health Initiative (2002) and its absence in cross-sex hormone therapy. See also Cass Review 2024 and Karolinska 2021.

Two opposing silhouettes — a 55-year-old man with documented deficiency and a young woman with a healthy body — separated by the question 'precautionary principle?'.

Abstract

Since the Women's Health Initiative trial (Rossouw et al., JAMA 2002), mainstream endocrinology has operated under a stringent precautionary regime — prescribing same-sex hormones only on documented indication, at the lowest effective dose, under periodic surveillance. In cross-sex hormone therapy, administered to endocrinologically unimpaired individuals at supra-physiological levels, this standard is not consistently applied. The Cass Review (NHS, 2024) characterised the underlying evidence base as "remarkably weak". The international reassessment (Finland 2020, Sweden 2021, UK 2024) effectively restores the endocrinological precautionary principle.

1. The paradox in one clinical question

Pose this question to an endocrinologist: why is testosterone prescribed with such caution to a 55-year-old man with laboratory-confirmed hypogonadism, while the same testosterone is delivered without comparable hesitation to an endocrinologically healthy 18-year-old woman seeking to masculinise her body? The question is rarely asked aloud — but it reveals the entire field of gender medicine as an exception to the endocrinological standard.

2. Mainstream caution since WHI 2002

For same-sex hormone replacement, the rules are clear: only on documented deficiency (hypogonadism, severe menopausal symptoms), lowest effective dose, shortest necessary duration, periodic monitoring of blood values, prostate, mammary tissue and liver function, and continuous weighing of thrombotic, cerebrovascular, oncological and cardiovascular risks. The Women's Health Initiative trial1 triggered a fundamental recalibration: hormone replacement in women caused more breast cancer and cardiovascular events than previously assumed. The directive has been unchanged since: prescribe sparingly, on clear indication, with regular evaluation.

3. The gender medicine exception

In gender medicine, the same hormones — often at considerably higher doses — are prescribed to persons without any underlying endocrine pathology:

  • A biological female reaches testosterone levels in the male range.
  • A biological male reaches female estrogen levels, combined with suppression of endogenous testosterone production.
  • In some settings, hormone therapy for adults is started under an informed consent model with an abbreviated assessment (WPATH SOC-8).
  • Long-term effects are inadequately studied — the Cass Review2 described the field as "an area of remarkably weak evidence", and the Dutch Health Council (2026) found the effects on cognition, fertility and the long term insufficiently studied (source).
  • In minors, puberty is first suppressed with GnRH analogues, which are licensed for precocious puberty (puberty that starts too early) — according to the Cass Review "a very different indication" from gender dysphoria (source).

4. Working with versus working against the body

Same-sex hormone replacement supports a system the body is designed for. Receptors, feedback loops, enzymes and target tissues are calibrated for the hormone in question. Cessation restores the natural state. Risks are primarily a function of dose and pre-existing comorbidity.

Cross-sex hormone administration does the opposite: exposure to a hormone the cellular architecture is not designed for, at levels exceeding the physiological range, with simultaneous suppression of endogenous production (anti-androgens, GnRH agonists). According to the Dutch Health Council (2026) the effects of treatment on cognition and fertility, and the long-term effects, are still insufficiently studied (source).

5. The numbers

Studies report the following risks and uncertainties:

  • Venous thromboembolism — in a US cohort, transfeminine participants had a higher incidence of VTE than cisgender men and women (8-year risk difference 16.7 per 1,000 relative to cisgender men), while the overall incidence of ischaemic stroke and myocardial infarction was similar across groups (Getahun 20183; source).
  • Cardiovascular events in transmasculine persons — the same US study found the evidence insufficient to draw conclusions on risk (Getahun 20183).
  • Bone density — in an Amsterdam cohort of 75 people, bone density Z-scores that fell during puberty suppression caught up with pre-treatment levels after long-term hormone treatment, except at the lumbar spine in participants assigned male at birth (van der Loos 20234; source); in a UK cohort of 70 adolescents on GnRH analogues, Z-scores fell significantly in the first year while absolute values did not change significantly (Joseph 20195; source).
  • Fertility — according to the Dutch Health Council (2026) the effects on fertility are still largely unclear; in transgender girls, GnRH analogues started in early puberty in principle lead to infertility unless they are willing to stop treatment for a long time, and in a very small number of treated girls sperm freezing was still not possible for most after more than 1.5 years of discontinuation (source).

A 55-year-old man on substitution remains within physiological serum values. A biological female on transition therapy is at male levels — outside the range her tissues were designed for. The difference is categorical, not gradual.

6. The linguistic problem

"Gender-affirming care" is a euphemism. Read literally, the term would mean confirming the biological sex; in practice, it remodels the body in the opposite direction.

7. International reassessment

The Cass Review (NHS, 2024), the Karolinska stop in Sweden (2021), the Finnish revision (Palveluvalikoima 2020) all restricted medical treatment of minors with gender dysphoria: in gender medicine, the medical standard that governs mainstream endocrinology is not consistently applied. In the UK, puberty blockers are no longer available as a routine commissioning treatment option for under-18s (NHS England, March 2024, source); in Sweden the National Board of Health and Welfare recommends GnRH analogues and gender-affirming hormones for minors only in exceptional cases and in a research setting (December 2022, source).

8. The unanswered question

A biological body responds to a hormone in the same way, regardless of the indication. The risks of cross-sex hormones are logically greater, not smaller. Nevertheless, the precautionary principle that has governed mainstream hormone medicine since 2002 is systematically disregarded in gender medicine. The answer is not medical but political and ideological — and that is precisely where the international reassessment now under way finds its core.

See also

Footnotes

  1. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-333.
  2. Cass H. Independent Review of Gender Identity Services for Children and Young People: Final Report. NHS England; April 2024.
  3. Getahun D, Nash R, Flanders WD et al. Cross-sex hormones and acute cardiovascular events in transgender persons. Annals of Internal Medicine 2018;169(4):205-213.
  4. van der Loos MATC, Vlot MC, Klink DT, Hannema SE, den Heijer M, Wiepjes CM. Bone mineral density in transgender adolescents treated with puberty suppression and subsequent gender-affirming hormones. JAMA Pediatr. 2023;177(12):1332-1341.
  5. Joseph T, Ting J, Butler G. The effect of GnRH analogue treatment on bone mineral density in young adolescents with gender dysphoria. J Pediatr Endocrinol Metab 2019;32(10):1077-1081.